Epigenomics Inks Distribution Deal with Pronto for Colorectal Cancer Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Epigenomics and Pronto Diagnostics today announced a distribution agreement for Epigenomics' Epi proColon colorectal cancer test in Israel.

Pronto, based in Tel Aviv, Israel plans to begin marketing the test in Israel next month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.